

**AMENDMENTS TO THE CLAIMS**

Applicant has submitted a new complete claim set showing marked up claims with insertions indicated by underlining and deletions indicated by strikeouts and/or double bracketing. This listing of claims will replace all prior versions and listings of claims in the application:

1-144 (Cancelled)

145. (Currently Amended) A method of inducing tumor cell death, comprising administering to a subject, a therapeutically effective amount of an anti-HLA-DR antibody effective to induce tumor cell death in HLA-DR-expressing tumor cells wherein the therapeutic outcome of the subject is improved following said administration, wherein said cancer is selected from the group consisting of multiple myeloma, lymphoma's including Hodgkin's lymphomas, and lymphocytic lymphomas, and leukemias.

146. (Previously Presented) The method of claim 145 wherein the anti-HLA-DR antibody is administered intravenously.

147. (Previously Presented) The method of claim 145 wherein the anti-HLA-DR antibody is administered parenterally.

148. (Allowed) A method for decreasing mitochondrial membrane potential in a mammalian cell, comprising

administering an MHC class II HLA-DR ligand to the mammalian cell to selectively engage MHC class II HLA-DR on the surface of the cell in an amount effective to decrease mitochondrial membrane potential in the mammalian cell, wherein the mammalian cell is not an antigen presenting cell, further comprising the step of contacting the mammalian cell with an amount of an MHC class II HLA-DR inducing agent effective to induce the expression of MHC class II HLA-DR on the surface of the mammalian cell, wherein the MHC class II HLA-DR ligand is an anti-MHC class II HLA-DR antibody.

149. (Previously Presented) The method of claim 145 wherein the subject is human.

150. (Allowed) The method of claim 148, wherein the mammalian cell is a human tumor cell.